title: CK-MM autoantibodies: prevalence, immune complexes, and effect on CK clearance.
abstract: Although the blood level of creatine kinase (CK) is the most commonly used marker of muscle injury, there is marked interindividual variability in this measure. Part of this variability may be attributed to variability in the rate of CK clearance from the circulation. In this study, we assessed the possibility that CK-MM autoantibodies form immune complexes with CK following muscle injury and subsequently affect the CK clearance rate. Using an enzyme-linked immunosorbent assay, CK-MM autoantibodies were detected in all 25 human subjects studied but the levels varied greatly. Using protein A-sepharose, the percentage of the plasma CK activity found in immune complexes was determined to be correlated with the CK-MM autoantibody level at lower CK levels (<1,022 U/L). When CK-MM antibodies were administered to mice, plasma CK activity following a bolus CK injection was reduced by 11%-32%. We conclude that CK-MM autoantibodies can modulate the rate of CK clearance from the circulation. Thus, the relatively low blood CK levels seen in some individuals following injury may be attributed partly or entirely to an autoantibody-enhanced clearance of CK.
authors.affiliation: Division of Physical Therapy, Georgia State University, Atlanta, Georgia 30302, USA. gwarren@gsu.edu
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Warren
authors.forename: Laura
authors.initials: L
authors.lastname: O'farrell
authors.forename: Karen R
authors.initials: KR
authors.lastname: Rogers
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Billings
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Sayers
authors.forename: Priscilla M
authors.initials: PM
authors.lastname: Clarkson
mesh_terms: D000328:Adult; D000818:Animals; D000936:Antigen-Antibody Complex / Q000276:immunology; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D052283:Creatine Kinase, MM Form / Q000097:blood* / Q000276:immunology*; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000201:enzymology / Q000276:immunology / Q000293:injuries; D009220:Myositis / Q000276:immunology* / Q000378:metabolism; D020721:Nervous System Autoimmune Disease, Experimental / Q000276:immunology / Q000378:metabolism; D054390:Receptors, CCR2; D019713:Receptors, CCR5 / Q000235:genetics; D019707:Receptors, Chemokine / Q000235:genetics; D016036:Seroepidemiologic Studies
chemical_list: D000936:Antigen-Antibody Complex; D001323:Autoantibodies; C515334:CCR2 protein, human; C515335:Ccr2 protein, mouse; D015850:Interleukin-6; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D052283:Creatine Kinase, MM Form